Differential regulation of LRRC37A2 in gastric cancer by DNA methylation. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Wisnieski, Fernanda; Geraldis, Jaqueline Cruz; Santos, Leonardo Caires; Leal, Mariana Ferreira; Calcagno, Danielle Queiroz; Gigek, Carolina Oliveira; Chen, Elizabeth Suchi; Anauate, Ana Carolina; Artigiani, Ricardo; Demachki, Samia; Assumpção, Paulo Pimentel; Lourenço, Laercio Gomes; Arasaki, Carlos Haruo; Krainer, Julie; Pabinger, Stephan; Burbano, Rommel Rodriguez; Smith, Marilia Arruda Cardoso
• Is Part Of: Epigenetics. Volume 17:Issue 1(2022)
• Page Start: 110
• Page End: 116
• Publication Date: 2022-01-02
• Subjects: DNA methylation -- gene expression -- cancer therapy -- LRRC37A2; Epigenesis -- Periodicals; Epigenetica; 572.86505
• DOI: 10.1080/15592294.2021.1878724
• Languages: English
• ISSNs: 1559-2294

Abstract

ABSTRACT: Gastric cancer (GC) is one of the leading types of fatal cancer worldwide. Epigenetic manipulation of cancer cells is a useful tool to better understand gene expression regulatory mechanisms and contributes to the discovery of novel biomarkers. Our research group recently reported a list of 83 genes that are potentially modulated by DNA methylation in GC cell lines. Herein, we further explored the regulation of one of these genes, LRRC37A2, in clinical samples. LRRC37A2 expression was evaluated by RT-qPCR, and DNA methylation was studied using next-generation bisulphite sequencing in 36 GC and paired adjacent nonneoplastic tissue samples. We showed that both reduced LRRC37A2 mRNA levels and increased LRRC37A2 exon methylation were associated with undifferentiated and poorly differentiated tumours. Moreover, LRRC37A2 gene expression and methylation levels were inversely correlated at the +45 exon CpG site. We suggest that DNA hypermethylation may contribute to reducing LRRC37A2 expression in undifferentiated and poorly differentiated GC. Therefore, our results show how some genes may be useful to stratify patients who are more likely to benefit from epigenetic therapy.Abbreviations: AR: androgen receptor; 5-AZAdC: 5-aza-2'-deoxycytidine; B2M : beta-2-microglobulin; GAPDH : glyceraldehyde-3-phosphate dehydrogenase; GC: gastric cancer; GLM: general linear model; LRRC37A2 : leucine-rich repeat containing 37 member A2; SD: standard deviation; TFII-I: general transcription factor II-I; TSS: transcription start site; XBP1: X-box binding protein 1